Multiple Myeloma definition
Examples of Multiple Myeloma in a sentence
Ø Patients with Hematologic malignancies (Ex. Leukemias, Iymphomas, Multiple Myeloma) and Pediatric malignancies (Any patient < 14 years of age) should be treated by qualified medical oncologist only.
This Agreement shall become effective upon the execution of this Agreement or a counterpart to this Agreement by each of the General Partner, SKM Limited Partners, TCP Limited Partners and ▇▇▇▇▇▇ Limited Partners listed on Schedule 3.3 hereto as of the date hereof and upon such effectiveness the Existing Agreement shall be superseded in its entirety hereby.
J&J Affiliate is a research-oriented pharmaceutical company active in the development and marketing of medicinal products within the Hematology area; - Organization is an organization dedicated to support patients with Multiple Myeloma and their relatives; - Organization has asked J&J Affiliate to support one of its projects and J&J Affiliate has agreed to provide support under the terms of this agreement.
In case of Multiple Myeloma, the malignant plasma cells accumulate in the bone marrow crowding out healthy blood cells, secreting inflammatory cytokines, thus causing anemia and immune suppression.
The Institution and the Investigator will conduct the study entitled “A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients with Multiple Myeloma (MM) diagnosed with Secondary Immunodeficiency (SID) ShortTitle: HyQvia NIS in MM patients with SID” (the “Study”) at Institution in accordance with the protocol, incorporated herein by reference (the “Protocol”).
Increased Mortality in Patients with Multiple Myeloma when OPDIVO is Added to a Thalidomide Analogue and Dexamethasone In clinical trials in patients with multiple myeloma, the addition of OPDIVO to a thalidomide analogue plus dexamethasone resulted in increased mortality.
MUDr. ▇▇▇▇▇ ▇▇▇▇▇, CSc. Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (ANCHOR)” (the “Study”), bearing protocol number OP-104, as may be amended from time to time (the “Protocol”), the provisions of which are incorporated herein by reference.
The PSG welcomes all patients with Multiple Myeloma, Lymphoma and Leukaemia and their families, friends and carers.
Following the Collaboration Term, Allogene shall use Commercially Reasonable Efforts to develop and commercialize at least one (1) Product for each of (a) the treatment at least one B-Cell Malignancy and (b) the treatment of Multiple Myeloma, in each case ((a) and (b)) in the United States and in the European Union.
BOSTON (Phase III trial, ongoing): Randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory Multiple Myeloma (rrmm).